BridgeBio Oncology Therapeutics
Biopharmaceutical company focused on developing precision medicines for genetic diseases and cancers driven by clear genetic causes, with a pipeline spanning rare diseases and oncology.
Notes
BridgeBio Oncology Therapeutics is the oncology-focused arm of BridgeBio Pharma, a biopharmaceutical company dedicated to discovering and developing life-changing medicines for patients with genetic diseases and cancers. BridgeBio takes a precision medicine approach, targeting diseases with well-understood genetic drivers.
The company operates through a network of subsidiary companies, each focused on specific disease areas, allowing for focused drug development while leveraging shared infrastructure and expertise. BridgeBio has built a diverse pipeline of programs across rare diseases and oncology indications.
Team
- Neil Kumar, Ph.D. - Founder and CEO of BridgeBio Pharma
- Charles Homcy, M.D. - Chief Medical Officer
- Leadership team with deep experience in drug development and precision medicine
Additional Research Findings
- Part of BridgeBio Pharma (publicly traded: BBIO)
- Raised $200 million in funding round (May 2024)
- Investor: Deerfield Management
- Focus on genetic diseases and cancers with clear genetic drivers
- Precision medicine approach
- Network of subsidiary companies for focused development
- Palo Alto headquarters
- Diverse pipeline across rare diseases and oncology
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Deerfield Management | New York, USA | biotech-focused | seedseries-a+3 | 3 |